Gilead wipes out most of Arcellx workforce

Gilead Lays Off 87% of Arcellx Workforce Post-Acquisition

Gilead Sciences completed its $7.8 billion acquisition of Arcellx, subsequently initiating layoffs that will affect 192 employees, representing an estimated 87% of Arcellx's workforce. The cuts are planned for sites in Redwood City, California, and Rockville, Maryland, with effective dates spanning from June 2026 to April 2027. The acquisition's centerpiece is Arcellx's investigational CAR T therapy, anitocabtagene autoleucel (anito-cel), which targets the BCMA protein for relapsed or refractory multiple myeloma. This therapy has received FDA fast track, orphan drug, and regenerative medicine advanced therapy designations and is currently under agency review with a target action date of December 23.

• Gilead is implementing significant workforce reductions at Arcellx, impacting 192 employees across its California and Maryland facilities. This represents an estimated 87% of Arcellx's 220-person staff as of March 1. Layoffs for 108 employees in Redwood City, California, are effective June 30, 2026, while 84 employees in Rockville, Maryland, will be laid off between June 30, 2026, and April 30, 2027.
• The layoffs follow Gilead's completion of its $7.8 billion acquisition of Arcellx on April 28, making the biotech a wholly owned subsidiary. The deal was primarily driven by Arcellx's investigational CAR T therapy, anitocabtagene autoleucel (anito-cel), designed to target the BCMA protein for relapsed or refractory multiple myeloma. Gilead's subsidiary, Kite Pharma, will now integrate anito-cel, leveraging its global manufacturing, regulatory, and commercial capabilities.
• Anitocabtagene autoleucel (anito-cel) is a late-stage CAR T therapy targeting the BCMA protein for the treatment of relapsed or refractory multiple myeloma. The therapy has garnered significant regulatory support, receiving Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy (RMAT) designations from the FDA. It is currently under review by the agency, with a target action date set for December 23.

Anito-cel's Strategic Fit in the Evolving Multiple Myeloma Landscape

The treatment landscape for relapsed or refractory multiple myeloma has undergone substantial transformation over the past five years, marked by the emergence of novel immunotherapeutic approaches and the refinement of established combination regimens. The most significant advancement has been the clinical integration of BCMA-directed therapies, including CAR-T cell therapies (ide-cel and cilta-cel) and bispecific T-cell engagers such as elranatamab, which received FDA approval in August 2023 for patients with at least four prior lines of therapy. These immunotherapies have demonstrated remarkable efficacy, with CAR-T therapy achieving an overall response rate of 86% and minimal residual disease negativity rate of 78%, though many patients still experience relapse within the first year. Concurrently, the identification of FLC suppression at Day +28 post-CAR-T as an early biomarker has emerged as a critical prognostic tool, with suppressed patients showing markedly superior outcomes (median PFS 23.4 vs 4.1 months).

The therapeutic armamentarium has expanded significantly through the approval of first-in-class agents including selinexor (nuclear export inhibitor) and the initial approval followed by subsequent withdrawal of belantamab mafodotin (BCMA antibody-drug conjugate) after the DREAMM-3 trial failed to demonstrate superiority over pomalidomide-dexamethasone despite achieving a 41% response rate. Daratumumab-based regimens have become increasingly established as standard of care, with meta-analyses demonstrating significant improvements in progression-free survival (HR 0.44) and overall response rates, while real-world data from Hungary showed the D-Rd regimen achieving 89% treatment response with median PFS of 22.0 months at first relapse. The IKEMA trial further validated the addition of isatuximab to carfilzomib-dexamethasone, establishing this triplet as a new standard of care with significantly improved PFS outcomes.

Despite these therapeutic advances, real-world outcomes data continue to highlight the challenging prognosis for heavily pretreated patients, particularly those with triple-class refractory disease who demonstrate median PFS of only 4.4 months and OS of 10.5 months with current standard of care approaches. The treatment landscape has become increasingly complex with the proliferation of combination options incorporating proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, histone deacetylase inhibitors, and alkylating agents, making optimal sequencing decisions more challenging for clinicians. This complexity underscores the continued unmet medical need in RRMM, despite the significant therapeutic progress achieved through novel immunotherapeutic modalities and refined combination strategies over the past five years.

Addressing Persistent Challenges in Relapsed/Refractory Multiple Myeloma

Despite significant therapeutic advances, relapsed/refractory multiple myeloma (RRMM) continues to present formidable clinical challenges. The disease remains incurable with most patients eventually experiencing relapse, even after achieving deep responses with novel therapies. Treatment complexity has increased substantially due to multiple available therapeutic options, requiring careful consideration of numerous patient and disease factors.

• Drug resistance development remains a major issue undermining treatment results, with patients often becoming resistant to standard treatments including immunomodulators, proteasome inhibitors, and anti-CD38 antibodies

• Limited therapeutic alternatives exist for patients who present with refractory disease or relapse after receiving the main classes of available drugs, representing a major clinical unmet need

• Complex treatment selection requires careful evaluation of previous treatment results, associated toxicities, biochemical markers for progression, disease dynamics, number of prior therapy lines, and underlying health status

• Novel therapy limitations include medium to long-term toxicities with new T cell redirection therapies (bispecific antibodies and CAR-T cells) that pose new healthcare challenges

• Resistance to BCMA-targeted therapies affects most patients who ultimately experience relapse despite initial deep and durable responses to CAR-T cell therapies and bispecific antibodies

• Poor outcomes in heavily pretreated patients with triple- and penta-exposed/refractory disease show poor survival rates even after advanced therapies like CAR-T cells and bispecific antibodies

• Balancing competing priorities among efficacy, toxicity, and cost represents a key ongoing challenge in treatment decision-making

• Ongoing clinical debates persist regarding the timing and effectiveness of salvage autologous stem cell transplant in RRMM patients

Anito-cel's Position in the BCMA-Targeted CAR T Arena

Several BCMA-targeted CAR-T cell therapies are being evaluated for relapsed/refractory multiple myeloma, sharing the same mechanism of action as anitocabtagene autoleucel. These therapies utilize genetically modified autologous T-cells engineered to target B-cell maturation antigen on plasma cells.

Additional BCMA-targeted approaches in development include bispecific T-cell engagers and antibody-drug conjugates, with elranatamab (ELREXFIO™) representing a notable bispecific CD3 T-cell engager that received FDA approval in August 2023 for heavily pretreated patients.

Gilead's $7.8B CAR T Play: High Stakes, High Potential

Gilead Sciences' substantial $7.8 billion acquisition of Arcellx marks a definitive move to bolster its presence in the high-stakes cell therapy and oncology sectors. The centerpiece of this strategic maneuver is anitocabtagene autoleucel (anito-cel), an investigational BCMA-targeted CAR T therapy poised for potential approval in relapsed or refractory multiple myeloma (r/r MM). With its FDA Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy (RMAT) designations, anito-cel is recognized for its potential to address a significant unmet need, offering a new therapeutic avenue for patients with limited options. The December 23 target action date for FDA review represents a critical near-term milestone that will validate this significant investment.

This acquisition strategically positions Gilead to become a more formidable player in the competitive multiple myeloma treatment landscape. A successful approval would not only expand Gilead's oncology portfolio but also establish it as a key innovator in the rapidly evolving CAR T space. However, this ambitious move is not without its considerations. The regulatory risk remains paramount; despite expedited pathways, FDA approval is never guaranteed, and a negative decision would have substantial financial repercussions. Furthermore, the planned layoffs impacting 87% of Arcellx's workforce, even with a phased approach, introduce integration and talent retention risks. Ensuring a seamless transfer of critical knowledge and expertise will be crucial for anito-cel's long-term success and future development. Lastly, the market competition in r/r MM is intense, requiring anito-cel to demonstrate a compelling profile to differentiate itself among existing and pipeline BCMA-targeted therapies. Gilead's ability to navigate these challenges will determine the ultimate impact of this significant strategic play.